Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Annexon Inc
(NQ:
ANNX
)
5.935
+0.025 (+0.42%)
Streaming Delayed Price
Updated: 9:31 AM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Annexon Inc
< Previous
1
2
Next >
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
August 12, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
August 05, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
July 11, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
June 25, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
June 18, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Pricing of $125 Million Underwritten Public Offering
June 05, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Proposed Public Offering of Common Stock
June 04, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
June 04, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
June 03, 2024
Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
May 13, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the Bank of America Health Care Conference
May 09, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
May 07, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
May 01, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024
From
Turnstone Biologics Corp.
Via
GlobeNewswire
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
March 26, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
February 21, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
January 07, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
December 20, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
December 20, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
December 20, 2023
From
Annexon Biosciences
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.